课题基金 / 基金详情

Aging and Innate immune system resilience in TBI

Aging and Innate immune system resilience in TBI
TBI 中的衰老和先天免疫系统恢复能力
批准号:
10369760
负责人:
PAULA C BICKFORD
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2026-03-31

项目摘要

项目成果

PAULA C BICKFORD的其他基金

相似基金

相关文献

中文摘要
翻译
创伤性脑损伤是包括慢性记忆在内的神经系统并发症的主要原因。 痴呆症等缺陷。与年轻患者相比,年龄较大的脑外伤患者预后恶化的风险更高 对口单位(Chou等人,2018年;Eight等人,2020年;Mganti等人,2016年;Ritzel等人,2019年),尽管 风险和更糟糕的结果,没有针对这一易感人群的靶向治疗,只有 很少有出版物关注针对这一弱势群体的治疗方法。数据显示,这种情况更加严重。 年龄较大的受试者可能对治疗干预表现出较低的反应性(Tajiri等人,2014),这可能 表明老年人将需要不同于年轻人的优化治疗。我们已经确定了一个 来自人类脂肪来源干细胞的治疗外显体(HASC Exo)(Patel等人,2018年) 幼年啮齿动物受伤后至少48小时的治疗窗口(见初步数据)。扩展后的 HASC exo的治疗窗将是相对于大多数当前实验疗法的重大进步, 治疗窗口只有几个小时,而不是几天。为了推动这一有希望的疗法向前发展,我们必须解决 我们对HASC exo的作用机制和有效性的认识存在严重差距 对不同年龄人群的干预。我们的假设是,这些HASC外切体的主要作用是 通过与免疫系统相互作用来调节对损伤的二级免疫反应。它已经很好了 证实在衰老的啮齿动物中,先天免疫细胞对损伤有夸大的反应。 我们的初步数据显示HASC exo在改善行为和减少炎症方面的有效性。 老年啮齿动物CCI后的标志物发生改变。因此,一个悬而未决的问题是,老龄化如何影响 对治疗的反应,特别是对HASC外切体的治疗。
英文摘要
Traumatic brain injury (TBI) is a leading cause of neurological complications including chronic memory deficits such as dementia. Older TBI patients are at a higher risk for worsening of outcomes than their younger counterparts (Chou et al., 2018; Early et al., 2020; Morganti et al., 2016; Ritzel et al., 2019), despite the higher risk and worse outcomes, there are no targeted therapies targeted for this susceptible population, and only a few publications looking at therapeutics for this vulnerable population. This is compounded by data suggesting that older subjects may show less responsiveness to therapeutic interventions (Tajiri et al., 2014) which may indicate that aged individuals will require optimized treatments that differ from young. We have identified a therapy exosomes from human adipose derived stem cells (hASC exo) (Patel et al., 2018) that have a therapeutic window up to at least 48 hours post injury in young rodents (see preliminary data). The extended therapeutic window of hASC exo would be a major advancement over most current experimental therapeutics, with a treatment window of only hours and not days. To move this promising therapy forward we must address critical gaps in our knowledge regarding hASC exo’s mechanism of action, and effectiveness of the intervention in diverse age populations. Our hypothesis is that a major action of these hASC exosomes is to modulate the secondary immune response to injury by interacting with the immune system. It is already well established that in aged rodents aged there is an exaggerated response of innate immune cells to the injury. Our preliminary data demonstrates the efficacy of hASC exo to improve behavior and reduce inflammatory markers following CCI is modified in aged rodents . Thus, an unanswered question is how aging impacts the response to treatment, and specifically treatment with hASC exosomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aging and Innate immune system resilience in TBI
  • 批准号:
    10616497
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    PAULA C BICKFORD
  • 依托单位:
ShEEP Request for QuantStudio 12K Flex Real-Time PCR system
  • 批准号:
    9796289
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    PAULA C BICKFORD
  • 依托单位:
BLRD Research Career Scientist Award Application
  • 批准号:
    10618267
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    PAULA C BICKFORD
  • 依托单位:
BLRD Research Career Scientist Award Application
  • 批准号:
    10265423
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    PAULA C BICKFORD
  • 依托单位:
海外基金